CGEM
Cullinan Oncology LLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$920.60M
P/E Ratio
—
EPS
$-3.36
Beta
-0.11
52W High
$16.74
52W Low
$5.68
50-Day MA
$13.51
200-Day MA
$9.68
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
6.74
PEG Ratio
—
About Cullinan Oncology LLC
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $18.94M |
| EBITDA | $-241.34M |
| Operating Margin | 0.00% |
| Return on Equity | -44.00% |
| Return on Assets | -28.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $6.79 |
| Price-to-Book | 2.14 |
| Price-to-Sales (TTM) | 25.86 |
| EV/Revenue | 11.55 |
| EV/EBITDA | -1.46 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $60.53M |
| Float | $43.21M |
| % Insiders | 0.42% |
| % Institutions | 105.50% |
Historical Volatility
HV 10-Day
59.34%
HV 20-Day
57.86%
HV 30-Day
55.03%
HV 60-Day
59.11%
HV Rank
26.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($31.35 target)
1
Strong Buy11
BuyData last updated: 4/10/2026